Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-04-23EMA Authorised: Taltz (ixekizumab) — Eli Lilly and Company (Ireland) Limited
EMA authorised Taltz (ixekizumab) from Eli Lilly for psoriasis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthri…
-
EMA approval · 2026-04-23EMA Authorised: Remsima (infliximab) — Celltrion Healthcare Hungary Kft.
EMA authorised Remsima (infliximab) from Celltrion Healthcare Hungary Kft. for multiple inflammatory diseases including rheumatoid arthritis…
-
EMA approval · 2026-04-23EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
EMA has authorised Amgevita (adalimumab) by Amgen Europe B.V., a biosimilar of adalimumab, for multiple inflammatory diseases including rheu…
-
EMA approval · 2026-04-16EMA Authorised: Steqeyma (ustekinumab) — Celltrion Healthcare Hungary Kft.
The EMA authorised Steqeyma (ustekinumab) by Celltrion Healthcare Hungary Kft for psoriasis, psoriatic arthritis, and Crohn's disease.
-
EMA approval · 2026-04-16EMA Authorised: Qoyvolma (ustekinumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Qoyvolma (ustekinumab) by Celltrion Healthcare Hungary Kft. for psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-04-15FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab submitted by Janssen Biotech, Inc. The action pertains to a supplemental submission …
-
EMA approval · 2026-03-30EMA Authorised: Imuldosa (ustekinumab) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Imuldosa (ustekinumab) from Accord Healthcare S.L.U. for Crohn's disease, psoriasis, and psoriatic …
-
EMA approval · 2026-03-30EMA Authorised: Uzpruvo (ustekinumab) — Stada Arzneimittel AG
EMA authorised Uzpruvo (ustekinumab) for the treatment of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
-
EMA approval · 2026-03-20EMA Authorised: Apremilast Accord (apremilast) — Accord Healthcare S.L.U.
The EMA has authorised Accord Healthcare's apremilast product (Apremilast Accord) for psoriatic arthritis, psoriasis, Behçet's syndrome, and…
-
EMA approval · 2026-03-19EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
EMA authorised Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, expanding treatment options in rheumatoid …
-
FDA approval · 2026-03-06FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ XR (tofacitinib) from Pfizer Laboratories Div Pfizer Inc, introducing the extended-r…
-
FDA approval · 2026-03-06FDA Approved: SKYRIZI — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for SKYRIZI (risankizumab-rzaa) from AbbVie Inc. The action updates or expands the drug's regulatory…
-
EMA approval · 2026-03-05EMA Authorised: Simponi (golimumab) — Janssen Cilag International NV
The European Medicines Agency authorised Simponi (golimumab) for multiple inflammatory conditions including rheumatoid arthritis, psoriatic …
-
EMA approval · 2026-03-04EMA Authorised: Otezla (apremilast) — Amgen Europe B.V.
The European Medicines Agency authorised Otezla (apremilast) for Behçet syndrome, in addition to its established uses in psoriatic arthritis…
-
EMA approval · 2026-02-25EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
The EMA authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, juvenil…
-
EMA approval · 2026-02-24EMA Authorised: Fymskina (ustekinumab) — Formycon AG
The EMA authorised Fymskina, an ustekinumab biosimilar from Formycon AG, for Crohn's disease, psoriasis, and psoriatic arthritis.
-
EMA approval · 2026-02-19EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Hulio, a biosimilar of adalimumab, for multiple inflammatory indications including hidradenitis suppurativa, psoriasis, u…
-
EMA approval · 2026-02-18EMA Authorised: Wezenla (ustekinumab) — Amgen Technology (Ireland) UC
EU authorization for Wezenla, a ustekinumab product from Amgen Technology (Ireland) UC, indicated for psoriasis, psoriatic arthritis, and Cr…
-
EMA approval · 2026-02-17EMA Authorised: Inflectra (infliximab) — Pfizer Europe MA EEIG
EMA authorised Inflectra (infliximab) as a biosimilar to Remicade for multiple inflammatory diseases including rheumatoid and psoriatic arth…
-
EMA approval · 2026-02-16EMA Authorised: Yesintek (ustekinumab) — Biosimilar Collaborations Ireland Limited
The European Medicines Agency authorised Yesintek, a biosimilar of ustekinumab, for use in psoriasis, psoriatic arthritis, and Crohn's disea…
-
EMA approval · 2026-02-05EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) as a biosimilar of adalimumab for several inflammatory and autoimmune diseases, including rheumatoid art…
-
EMA approval · 2026-02-04EMA Authorised: Imraldi (adalimumab) — Samsung Bioepis NL B.V.
EMA authorised Imraldi, a biosimilar adalimumab by Samsung Bioepis NL B.V., for multiple inflammatory diseases including ankylosing spondyli…
-
EMA approval · 2026-01-28EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EMA authorised Hukyndra (adalimumab) from Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, psoriati…
-
EMA approval · 2026-01-28EMA Authorised: Leflunomide Zentiva (previously Leflunomide Winthrop) (leflunomide) — Zentiva k.s.
The EMA has authorised Leflunomide Zentiva for use in rheumatoid arthritis and psoriatic arthritis.
-
EMA approval · 2026-01-27EMA Authorised: Cimzia (certolizumab pegol) — UCB Pharma
The European Medicines Agency authorised Cimzia (certolizumab pegol) for treatment of rheumatoid arthritis and other inflammatory diseases, …